GLP-1 for Weight Loss When You Do Not Have Diabetes: Separating Fact from Confusion

The confusion is understandable

GLP-1 medications were first approved for type 2 diabetes. Many people still associate them exclusively with diabetes treatment. But the FDA has approved specific GLP-1 medications — Wegovy (semaglutide) and Zepbound (tirzepatide) — for chronic weight management in people without diabetes. Understanding this distinction matters because it affects insurance coverage, prescribing conventions, and how people think about their eligibility.

The biology does not require diabetes

GLP-1 receptor agonists work by mimicking a natural hormone that regulates appetite, digestion speed, and insulin release. These mechanisms are relevant whether or not someone has diabetes. People without diabetes still have GLP-1 receptors, still experience appetite and satiety signaling, and still benefit from the metabolic effects of GLP-1 receptor activation.

Eligibility criteria for weight loss without diabetes

FDA-approved indications for GLP-1 weight loss medications specify: BMI of 30 kg/m2 or higher, or BMI of 27 kg/m2 or higher with at least one weight-related health condition such as hypertension, dyslipidemia, or obstructive sleep apnea. These criteria apply whether or not someone has diabetes. A provider evaluates your BMI, health history, current medications, and treatment goals to determine eligibility.

The insurance problem — not a medical one

Many insurers historically covered GLP-1 medications only for diabetes. This created a widespread misconception that these medications are only for diabetes. The distinction was always about insurance coverage policy — not medical appropriateness. The coverage landscape is changing, with Medicare now permitting Part D coverage for weight loss and more employer plans adding coverage.

Compounded GLP-1: the access pathway

For people without diabetes who do not have insurance coverage for brand-name weight loss medications, compounded GLP-1 preparations accessed through telemedicine platforms represent an alternative pathway. A provider evaluates each patient individually and determines if treatment is medically appropriate.